What is Progentec Diagnostics?
Progentec Diagnostics, Inc. is at the forefront of proactive care solutions for systemic lupus erythematosus, multiple sclerosis, and other autoimmune diseases. Leveraging advanced proteomics and digital health technologies, the company offers the aiSLE DX Family of Tests designed to predict disease flares and monitor activity. Their commitment extends to patient empowerment through platforms like LupusCorner, which provides essential health management resources and community support. Progentec's unique combination of proprietary blood biomarkers and remote digital monitoring aims to revolutionize patient care on a global scale.
How much funding has Progentec Diagnostics raised?
Progentec Diagnostics has raised a total of $5.2M across 2 funding rounds:
Series A
$5M
Debt
$172K
Series A (2020): $5M with participation from Mayo Clinic, Plains Venture Partners, Oklahoma Seed Capital Fund, Oklahoma Medical Research Foundation, NMC Health, Burns & Stowers Investments LLC, OCA Ventures, Stanford University, and Oklahoma Angel Capital Fund II
Debt (2021): $172K led by PPP
Key Investors in Progentec Diagnostics
Mayo Clinic
Mayo Clinic, a globally recognized nonprofit healthcare organization, specializes in integrated clinical practice, education, and medical research, contributing significantly to advancements in complex health conditions and healthcare innovation.
OCA Ventures
OCA Ventures is focused on empowering entrepreneurs by providing essential support and resources to foster innovation and growth within emerging businesses, aiding them in developing successful companies.
Stanford University
Stanford University, a leading research institution, is renowned for its entrepreneurial spirit and interdisciplinary approach to problem-solving, driving innovation across various fields from its California base.
What's next for Progentec Diagnostics?
The substantial enterprise-level funding positions Progentec Diagnostics for accelerated growth and market expansion. This capital infusion is expected to fuel further research and development, enhance the scalability of their diagnostic platforms, and broaden their reach to patients worldwide. The strategic nature of the recent investment suggests a focus on strengthening market presence and potentially forging key partnerships within the healthcare ecosystem. Progentec's trajectory indicates a move towards becoming a dominant player in the digital health and diagnostics space for autoimmune conditions.
See full Progentec Diagnostics company page
